227 related articles for article (PubMed ID: 18274998)
1. Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.
Simunek T; Sterba M; Popelova O; Kaiserova H; Potacova A; Adamcova M; Mazurova Y; Ponka P; Gersl V
Hemoglobin; 2008; 32(1-2):207-15. PubMed ID: 18274998
[TBL] [Abstract][Full Text] [Related]
2. Cardioprotective effects of a novel iron chelator, pyridoxal 2-chlorobenzoyl hydrazone, in the rabbit model of daunorubicin-induced cardiotoxicity.
Sterba M; Popelová O; Simunek T; Mazurová Y; Potácová A; Adamcová M; Kaiserová H; Ponka P; Gersl V
J Pharmacol Exp Ther; 2006 Dec; 319(3):1336-47. PubMed ID: 17003229
[TBL] [Abstract][Full Text] [Related]
3. Iron chelation-afforded cardioprotection against chronic anthracycline cardiotoxicity: a study of salicylaldehyde isonicotinoyl hydrazone (SIH).
Sterba M; Popelová O; Simůnek T; Mazurová Y; Potácová A; Adamcová M; Guncová I; Kaiserová H; Palicka V; Ponka P; Gersl V
Toxicology; 2007 Jun; 235(3):150-66. PubMed ID: 17459556
[TBL] [Abstract][Full Text] [Related]
4. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits.
Simůnek T; Klimtová I; Kaplanová J; Sterba M; Mazurová Y; Adamcová M; Hrdina R; Gersl V; Ponka P
Pharmacol Res; 2005 Mar; 51(3):223-31. PubMed ID: 15661572
[TBL] [Abstract][Full Text] [Related]
5. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
[TBL] [Abstract][Full Text] [Related]
6. The interaction of pyridoxal isonicotinoyl hydrazone (PIH) and salicylaldehyde isonicotinoyl hydrazone (SIH) with iron.
Chen YL; Kong X; Xie Y; Hider RC
J Inorg Biochem; 2018 Mar; 180():194-203. PubMed ID: 29329026
[TBL] [Abstract][Full Text] [Related]
7. Orally effective iron chelators for the treatment of iron overload disease: the case for a further look at pyridoxal isonicotinoyl hydrazone and its analogs.
Richardson DR; Ponka P
J Lab Clin Med; 1998 Oct; 132(4):351-2. PubMed ID: 9794707
[No Abstract] [Full Text] [Related]
8. Mechanism of in vivo iron chelation by pyridoxal isonicotinoyl hydrazone and other imino derivatives of pyridoxal.
Hershko C; Avramovici-Grisaru S; Link G; Gelfand L; Sarel S
J Lab Clin Med; 1981 Jul; 98(1):99-108. PubMed ID: 7252329
[TBL] [Abstract][Full Text] [Related]
9. Oxidative stress mediates toxicity of pyridoxal isonicotinoyl hydrazone analogs.
Buss JL; Neuzil J; Ponka P
Arch Biochem Biophys; 2004 Jan; 421(1):1-9. PubMed ID: 14678779
[TBL] [Abstract][Full Text] [Related]
10. HPLC study on stability of pyridoxal isonicotinoyl hydrazone.
Kovaríková P; Mokrý M; Klimes J; Vávrová K
J Pharm Biomed Anal; 2006 Jan; 40(1):105-12. PubMed ID: 16061341
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the stability of aromatic hydrazones in plasma and related biological material.
Kovaríková P; Mrkvicková Z; Klimes J
J Pharm Biomed Anal; 2008 Jun; 47(2):360-70. PubMed ID: 18294799
[TBL] [Abstract][Full Text] [Related]
12. Pyridoxal isonicotinoyl hydrazone analogs induce apoptosis in hematopoietic cells due to their iron-chelating properties.
Buss JL; Neuzil J; Gellert N; Weber C; Ponka P
Biochem Pharmacol; 2003 Jan; 65(2):161-72. PubMed ID: 12504792
[TBL] [Abstract][Full Text] [Related]
13. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease.
Richardson DR; Ponka P
J Lab Clin Med; 1998 Apr; 131(4):306-15. PubMed ID: 9579383
[TBL] [Abstract][Full Text] [Related]
14. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
15. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
Bláha K; Cikrt M; Nerudová J; Ponka HF
Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
[TBL] [Abstract][Full Text] [Related]
16. Development of novel aroylhydrazone ligands for iron chelation therapy: 2-pyridylcarboxaldehyde isonicotinoyl hydrazone analogs.
Becker E; Richardson DR
J Lab Clin Med; 1999 Nov; 134(5):510-21. PubMed ID: 10560945
[TBL] [Abstract][Full Text] [Related]
17. The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro.
Schröterová L; Kaiserová H; Baliharová V; Velík J; Gersl V; Kvasnicková E
Physiol Res; 2004; 53(6):683-91. PubMed ID: 15588138
[TBL] [Abstract][Full Text] [Related]
18. EPR spin trapping and 2-deoxyribose degradation studies of the effect of pyridoxal isonicotinoyl hydrazone (PIH) on *OH formation by the Fenton reaction.
Hermes-Lima M; Santos NC; Yan J; Andrews M; Schulman HM; Ponka P
Biochim Biophys Acta; 1999 Feb; 1426(3):475-82. PubMed ID: 10076064
[TBL] [Abstract][Full Text] [Related]
19. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis.
Richardson DR; Ponka P
J Lab Clin Med; 1994 Nov; 124(5):660-71. PubMed ID: 7964124
[TBL] [Abstract][Full Text] [Related]
20. Analogues of pyridoxal isonicotinoyl hydrazone (PIH) as potential iron chelators for the treatment of neoplasia.
Richardson DR
Leuk Lymphoma; 1998 Sep; 31(1-2):47-60. PubMed ID: 9720714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
